Merck and Co. Revenue and Competitors

Kenilworth, NJ USA

Location

$5.6M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Merck and Co.'s estimated annual revenue is currently $52.6B per year.(i)
  • Merck and Co.'s estimated revenue per employee is $815,141
  • Merck and Co.'s total funding is $5.6M.
  • Merck and Co.'s current valuation is $205.6B. (January 2022)

Employee Data

  • Merck and Co. has 64541 Employees.(i)
  • Merck and Co. grew their employee count by 4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5702.6M283714%N/AN/A
Add Company

Merck is a leading research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck-Medco manages pharmacy benefits for employers, insurers and other plan sponsors, encouraging the appropriate use of medicines and providing disease management programs. Through these complementary capabilities, Merck works to improve quality of life and contain overall health-care costs

keywords:N/A

$5.6M

Total Funding

64541

Number of Employees

$52.6B

Revenue (est)

4%

Employee Growth %

$205.6B

Valuation

N/A

Accelerator

Merck and Co. News

2022-04-20 - Merck, Lilly, Bristol Earnings Could Prove Big Pharma's Defensive Value

Merck's call is scheduled for 8 a.m. on Thursday. Finally, Gilead shares are down 15% this year. Analysts expect EPS of $1.80, according to...

2022-04-17 - Merck Announces That Joseph Romanelli Will Lead Merck ...

Romanelli returns to Merck after serving as chief executive officer of JiXing Pharmaceuticals, a China-based biopharmaceutical company, since...

2022-04-17 - Chutes & Ladders—Romanelli returns to Merck to lead ...

Chutes & Ladders—Romanelli returns to Merck to lead international human health team after brief CEO stint. By Max Bayer Apr 22, 2022 06:30am.

2016-06-10 - Healthcare Company Merck to Buy Afferent Pharmaceuticals For up to $1.25 Billion

Global health care company Merck (NYSE:MRK), is to acquire* Afferent Pharmaceuticals, a San Mateo, CA-based pharmaceutical company that develops therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions, for up to $1.25 billion. Founde ...